Harmony Biosciences (HRMY) Stock Forecast & Price Target
Score
Harmony Biosciences Holdings, Inc. price target
| HRMY | |
|---|---|
| Low | $34.00 |
| Average | $48.67 |
| High | $70.00 |
| Upside vs current price | +44.2% |
The average target of $48.67 is +44.2% versus the current HRMY price of $33.76.
Harmony Biosciences Holdings, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 2 |
| Buy | 6 |
| Hold | 3 |
| Sell | 0 |
| Strong sell | 1 |
| Consensus | Buy |
12 analysts cover HRMY.
Harmony Biosciences Holdings, Inc. EPS and revenue estimates
Published annual figures for HRMY on this page are 2026 EPS $3.91, 2027 EPS $4.45. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $3.91 | $1.03B |
| 2027 | $4.45 | $1.17B |
Is Harmony Biosciences Holdings, Inc. a buy or sell?
Of the 12 analysts covering Harmony Biosciences Holdings, Inc., 8 rate it a buy (2 strong buy and 6 buy), 3 rate it a hold, and 1 rates it a sell (0 sell and 1 strong sell).
The HRMY consensus label is Buy, beside 8 buy-side ratings and 1 sell-side ratings.
The average target of $48.67 implies +44.2% versus the current price of $33.76.
The HRMY rating block is 12 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Harmony Biosciences Holdings, Inc. forecast
A wide spread is the story on HRMY. Targets run from $34.00 to $70.00, with $48.67 as the average.
The gap from the $33.76 price to the HRMY average is +44.2%.
The HRMY rating mix is lopsided rather than split: 8 of 12 analysts are on the buy side, 3 are at hold, and 1 is on the sell side, and the published consensus is Buy.
Month by month, the HRMY average target is higher ($49.00) than the quarterly average ($43.50).
With 12 analysts on HRMY, the average is a small sample.
Harmony Biosciences Holdings, Inc. forecast questions
What is the HRMY price target?
The published range for HRMY is $34.00 to $70.00, with an average of $48.67. That average is +44.2% versus the current price of $33.76.
Is Harmony Biosciences Holdings, Inc. a buy or sell?
Of the 12 analysts covering Harmony Biosciences Holdings, Inc., 8 rate it a buy, 3 rate it a hold, and 1 rates it a sell. The consensus is Buy, leaving HRMY at 8 buy ratings, 3 holds, and 1 sells.
What is the EPS estimate for Harmony Biosciences Holdings, Inc.?
Analyst EPS estimates for Harmony Biosciences Holdings, Inc.: 2026 $3.91, 2027 $4.45.
What is the revenue estimate for Harmony Biosciences Holdings, Inc.?
Analyst revenue estimates for Harmony Biosciences Holdings, Inc.: 2026 $1.03B, 2027 $1.17B.
How many analysts cover HRMY?
12 analysts cover HRMY. Their consensus on HRMY is Buy, across those 12.